Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)
Funds one bundled run from first-in-human through phase 2a for a dementia drug that works on something other than amyloid or tau.
Early dementia drug development loses years to the gaps between trials — each phase written, reviewed and funded separately while the compound waits. The National Institutes of Health funds the whole early stretch as one project here.
The applicant bundles independent protocols: a phase 1 trial together with phase 1b and phase 2a trials. They stay separate protocols, but they are planned, funded …
Bundled phase 1, phase 1b and phase 2a clinical trials of pharmacological candidates — small molecules or biologics — engaging non-amyloid and non-tau mechanisms to address cognitive or neuropsychiatric symptoms across the spectrum of Alzheimer's disease and related dementias, with prespecified go/no-go safety and tolerability milestones gating the advance between phases.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up